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Insulin resistance in adult polycystic kidney disease. Adult polycystic
kidney disease (APKD) is a common hereditary disease with renal and
extra-renal manifestations. There are at least three genes responsible for
this disease. The polycystic kidney disease 1 (PKD1) gene product is a
membrane protein involved in cell-cell and cell-matrix interactions and
has a widespread tissue distribution. Abnormal membrane fluidity in
erythrocytes from APKD patients is due to altered membrane proteins.
Membrane fluidity of mononuclear cells is related to whole body insulin
sensitivity. Insulin sensitivity might therefore be disturbed in APKD if the
erythrocyte membrane abnormality is also present in other cells. There-
fore, we investigated insulin sensitivity in 15 APKD patients and 20 normal
subjects matched for age and sex. Insulin sensitivity was assessed by a short
insulin tolerance test to derive the first-order rate constant for the
disappearance of glucose (Kitt) and mononuclear leukocyte membrane
fluidity was measured by fluorescence anisotropy. The Kitt value (% mmol
• liter1 min) was lower in APKD patients than in normal subjects
[median (range) 2.2 (1.5 to 6.3) vs. 4.1 (2.0 to 5.4), P < 0.001]. Fasting
plasma insulin concentrations were negatively correlated with the Kitt
values (r = —0.66, P < 0.001). Core region anisotropy was significantly
lower (higher fluidity) in leukocytes from APKD patients [mean (sEM)
0.164 (0.003) vs. 0.174 (0.001), P < 0.0011. Insulin sensitivity was positively
correlated with the fluorescence anisotropy of the core region of leukocyte
membranes (r = 0.81, P = 0.0001). In conclusion, APKD patients were
insulin resistant and some patients were hyperinsulinemic, which may
indicate increased cardiovascular risk. The cellular basis of the insulin
resistance may be directly related to the proteins causing the disease or to
the general change in membrane properties.
Adult polycystic kidney disease (APKD) is a common heredi-
tary disease with a prevalence of I in 1000, and accounts for
approximately 10% of the patients who are on renal replacement
therapy [1]. There are at least three genes responsible for APKD.
The major gene is polycystic kidney disease 1 (PKD I), mapped to
the short arm of chromosome 16 [2], which accounts for more
than 80% of APKD patients in northern Europe. The product of
this gene has been described recently [3] and named polycystin [4].
From structure predictions it has been suggested that polycystin is
an integral membrane protein involved in cell-cell and cell-matrix
interactions [4]. It has been shown that polycystin is widely
expressed in several human tissues [5]. Recently, it has been
postulated that one function of polycystin is to suppress renal
epithelial cell growth [6]. The second gene, PKD 2, is on chro-
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mosome 4q13-q23 [7] and has also been predicted to encode for
an integral membrane protein, in this case resembling calcium and
sodium channels [8]. It has been suggested that the PKD 1 gene
might act as the regulator of the PKD 2 channel activity; hence,
this raises the possibility that the phenotype of APKD may be
partly due to a defect of a transport system that is at present
unknown [8]. Recently evidence of a third gene, for which the
gene locus is yet to be mapped, has been reported [9].
We have previously demonstrated that the membrane fluidity,
measured by steady-state fluorescence polarization, of intact
erythrocytes from APKD patients is higher than that from normal
subjects [10]. This abnormality was not detected in erythrocyte
ghost membranes, which indicates that the abnormality of the
membrane lipid bilayer organization depends on the membrane
cytoskeleton. Additionally, we studied the function of the eryth-
rocyte membrane organization in APKD patients using sodium-
lithium countertransport (Na/Li CT) as a probe, and observed
abnormalities in the kinetics of Na/Li CT that may involve
cytoskeleton-lipid bilayer interactions [11].
Recently, data in this laboratory have demonstrated an inverse
relationship between mononuclear leukocyte membrane fluidity
(reciprocal of fluorescence anisotropy) and whole body insulin
sensitivity [12]. This observation indicates that an altered organi-
zation of membrane proteins and lipids may disturb the action of
insulin and lead to insulin resistance. In addition, abnormal
erythrocyte Na/Li CT is also related to insulin resistance [13].
Since we have shown that APKD patients have the membrane
abnormalities associated with insulin resistance, it seemed reason-
able to hypothesize that if there was a mechanistic relation
between increased membrane fluidity and insulin resistance, then
APKD patients would also be insulin resistant. This hypothesis
was tested using a short insulin tolerance test to evaluate insulin
sensitivity, and relating this to mononuclear cell membrane fluid-
ity.
METHODS
Subjects
Fifteen Caucasian patients with APKD, aged between 18 and 70
years old, were studied. The diagnosis of APKD was based on the
demonstration of multiple bilateral renal cysts by ultrasound and
a family history of the disease. Seven APKD patients had hyper-
tension and eight were normotensive. Four hypertensive APKD
patients were on a beta blocker (Atenolol), two on angiotensin-
converting enzyme inhibitor and one on both an angiotensin-
converting enzyme inhibitor and a diuretic. Twenty normal sub-
jects, matched for age and sex with APKD patients, with no family
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Table 1. Clinical characteristics of APKD patients and normal controls
NC
APKD
All NT HT
Male/female 12/8 8/7 5/3 3/4
Age years 40 2 42 3 42 6 44 4
Blood pressure
Systolic
Diastolic
120 3
72 2 128 3l81 11) 125 280 1 132 583 1
Plasma creatinine 0.93 0.97 0.95 0.99
mg/dl (0.73—1.18) (0.86—1.24) (0.86—1.10) (0.88—1.24)
Creatinine clearance 99 102 97 102
rnl/rnin/1.73 rn2 (80—1 29) (81—125) (81—1 19) (81—125)
Plasma cholesterol 201 197 182 197
rng/dl (158—247) (124—236) (124—236) (158—216)
Plasma triglycerides 80 80 80 88
rng/dl (35—142) (62—124) (62—124) (62—106)
Body mass index
kg/rn2
23.5
(21.7—26.4)
22.8
(21.9—28.5)
22.6
(22.0—28.5)
22.9
(21.9—26.6)
Fasting blood 82 2 83 2 83 2 83 3
rng/dl sugar
Plasma insulin 2.3 0.1 6.4 0.8° 5.8 0.8 7.3 1.6
mU/liter
Values are mean SEM and median (range). Abbreviations are: NC,
normal controls; APKD, adult polycystic kidney disease patients; NT,
normotensive APKD patients; HT, hypertensive APKD patients.
P < 0.001, 'P < 0.05 for all APKD patients vs. normal controls
history of hypertension or diabetes mellitus, were studied for
comparison. All APKD patients and normal subjects had serum
creatinine less than 1.35 mg/dl. Their glomerular filtration rates
(GFR) were assessed by creatinine clearance using the Cockcroft
and Gault's formula [14J. A single shot inulin study was performed
on seven hypertensive APKD patients to assess glomerular filtra-
tion rate (GFR) and the mean (sEM) of their GFR was 114 (7)
mI/mm/i .73 m2. Clinical characteristics of APKD patients and
normal controls are shown in Table 1. This study was approved by
the Joint Ethical Committee of the Newcastle Health Authority
and University of Newcastle-upon-Tyne. All subjects gave their
informed consent to the study.
Insulin sensitivity test
Insulin sensitivity was assessed by the short insulin tolerance
test (ITF), which has been validated against the euglycamic clamp
[15J. On the morning of the short ITT after an overnight fast, two
Teflon cannulae were inserted under local anesthesia. One placed
retrogradely in a hand vein was used for blood sampling for
glucose and insulin measurements. The second cannula was
inserted in a contralateral antecubital vein and was used for all
infusions. Venous blood was arterialized by maintaining the hand
at approximately 55°C in a thermoregulated plexiglass box. A
period of 30 minutes following cannulation was allowed for
baseline stabilization. Basal blood was taken into lithium heparin
tubes to measure plasma glucose and plasma insulin. Thereafter,
subjects were intravenously injected with Human Actrapid insulin
(Novo Laboratories, Basingstoke, UK) 0.05 U kg' body wt, and
then blood samples were taken every minute for 15 minutes from
an arterialized hand vein for blood glucose determination. At the
end of the test subjects were given a glass of Lucozade to bring
their blood glucose back to the pre-study levels.
Plasma glucose was measured immediately after the test by a
glucose oxidase method using the Yellow Springs analyzer (Yel-
low Springs Instruments, Yellow Springs, OH, USA). The insulin
sensitivity of the whole body was indicated by the first-order rate
constant for disappearance of glucose, Kitt (% mmol liter1
min 1),whichwas estimated from the slope of the regression line
for the logarithm of plasma glucose against time during the first 3
to 15 minutes of the test (multiplied by —100).
Venous blood was collected into lithium heparin tubes. After
centrifugation (2000 g for 4 mm at 5°C), plasma was separated and
stored at —80°C before the free insulin concentration was mea-
sured by an enzyme linked immunosorbent assay (ELISA, DAKO
Insulin, UK).
Mononuclear cell preparation
Venous blood was collected into tubes containing lithium
heparin, diluted 1:1 with phosphate-buffered saline (PBS), layered
onto Ficoll-Hypaque (d = 1.077) and centrifuged at 400 g for 25
minutes. The mononuclear cell layer was then washed with PBS
and centrifuged at 250 g for 15 minutes to remove platelets and
resuspended in PBS. A cell count of the suspension was then
determined and the lymphocyte concentration adjusted as re-
quired for fluorescence anisotropy.
Cell membrane fluidity measurement
Membrane fluidity of the superficial and core membrane re-
gions were probed by the fluorescence anisotropies of trimethyl-
ammonium-diphenylhexatriene (TMA-DPH) and 1,6-diphenyl-
1,3,5-hexatriene (DPH), respectively. The fluorescence anisotropy
values were measured with a Perkin-Elmer LS 50B luminescence
spectrometer at 37°C with excitation and emission wavelengths of
360 and 430 nm, respectively, and slit widths of 10 nm. Anisotropy
(A) was calculated according to the equations:
A — 1w
— G x Ivh
—
1w + 2G x Ivh
G=
Ihh
where 1w and Ivh are the intensities with the excitation polarizer
in the vertical (v) position and the emission polarizer in the
vertical (v) or horizontal (h) position, respectively. G is the
correction factor for the optical system and was determined
before each measurement of anisotropy.
Statistical analysis
In the groups studied, the results of variables that were
normally distributed are given as mean SEM and those that were
not normally distributed are given as median and range. The
unpaired t-test was used to test the significance of differences of
normally distributed variables between groups. The Mann-Whit-
ney U-test was used to test for the significance of differences of
Kitt between groups. Relationships were evaluated with Pearson's
correlation coefficient (r) and least-squares regression analysis.
Spearman correlation coefficient was used to test the relationship
between DPH anisotropy and Kitt in APKD patients.
RESULTS
The APKD patients were clearly insulin resistant. Insulin
sensitivity as measured by Kitt (% nimol liter' min1) was
significantly lower in APKD patients than that in normal subjects
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Fig. 2. Fluorescence anisotropies of TMA-DPH and DPH of mononu-
clear leukocytes from normal controls (NC) and adult polycystic kidney
disease (APKD) patients. Bars indicate the median.
[median (range) 2.2 (1.5 to 6.3) versus 4.1 (2.0 to 5.4), P < 0.001]
and fasting plasma insulin (mU liter') was higher [mean (sEM)
6.4 (0.8) versus 2.3 (0.1), P = 0.00011. The Kitt values of APKD
patients were not normally distributed and almost all the APKD
patients had low Kitt values. The Kitt values of normal subjects
and APKD patients were inversely related to fasting plasma
insulin (r =
—0.66, P < 0.001). Two patients with the lowest Kitt
values had significant fasting hyperinsulinemia at 12.2 and 11.9
mU - liter1 (normal reference range, 1.6 to 10.9 mU liter1).
The Kitt values of hypertensive APKD patients were similar to
those observed in normotensive APKD patients (Fig. 1).
The fluorescence anisotropy of DPH in mononuclear leuko-
cytes from APKD patients was significantly lower than that from
normal subjects [mean (saM) 0.164 (0.003) vs. 0.174 (0.001), P <
0.001; Fig. 2]. Therefore, the membrane fluidity at the core region
of mononuclear cells was higher in APKD patients. The superfi.
cial region membrane fluidity, as measured by fluorescence an-
isotropy of TMA-DPH, was also higher in leukocytes from APKD
Insulin sensitivity (Kitt)
Fig. 3. Relationship between insulin sensitivity (Kitt) and diphenyl-
hexatriene (DPH) fluorescence anisotropy in normal controls (0) and
adult polycystic kidney disease (APKD; •) patients. y = 0,006x + 0.149,
r = 0.81, and P = 0.0001.
patients than that from normal subjects [mean (sEM) 0.264 (0.002)
vs. 0.269 (0.001), P < 0.01; Fig. 2].
The insulin sensitivity of the whole body as assessed by Kitt was
positively correlated with the fluorescence anisotropy of DPH
(r = 0.81, P = 0.0001; Fig. 3) in normal controls and APKD
patients, but not with the fluorescence anisotropy of TMA-DPH
(r = 0.18, P = 0.31). The relationship between DPH anisotropy
NC APKD and Kitt in the normal controls alone was r = 0.64, P = 0.003 and
in the APKD patients alone it was r = 0.49, P = 0.06.
There was no significant difference in the body mass index,
plasma triglycerides, plasma cholesterol or creatinine clearance
between normal subjects and APKD patients, nor between nor-
motensive and hypertensive APKD patients (Table 1).
DISCUSSION
Insulin resistance is characterized by an impaired insulin-
mediated glucose metabolism and subsequently causes high
plasma insulin levels needed to maintain normal blood glucose
levels [16]. It is clearly a characteristic of non-insulin-dependent
diabetes mellitus (NIDDM) and the related conglomerate of the
so-called metabolic syndrome, but it is also found in other,
apparently unrelated, diseases such as polycystic ovary syndrome
[17]. Insulin resistance is also found in a proportion of otherwise
normal subjects [18]. However, the cellular defect leading to the
underlying phenomenon of insulin resistance remains unclear.
The present study is the first to our knowledge to show that in
adult polycystic kidney disease (APKD) there is also a marked
reduction in the sensitivity to insulin. It is generally accepted that
the Kitt value of 2.6% mmol liter1 min1 or lower indicates an
insulin resistant state [15]. In the original study of Akinmokun et
al [15], the Kitt values were 4.2 0.1 for normal controls and
2.0 0.1 for NIDDM patients. In a recent study, the Kitt values
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Fig. 1. Distribution of Kitt values (% mmol liter'' min') of normal
controls (NC), normotensive APKD patients (APKD/NT) and hyperten-
sive APKD patients (APKJJffF). Bars indicate the median.
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were 3.5 0.3 for normal controls and 1.3 0.2 for NIDDM
patients [12]. In this present study the Kitt value of the normal
control group was comparable to those two studies. There is
evidence suggesting that approximately 15 to 20% of the normal
population are insulin insensitive [19], and this is consistent with
the result of Kitt in normal controls in this current study (2 of 20
normal subjects had Kitt values less than 2.6% mmol liter1
min'). The degree of insulin resistance assessed by the Kitt in
APKD patients in our present study with the median and range of
2.2 (1.5 to 6.3) was less severe than that observed in NIDDM
patients. However, 10 of 15 APKD patients had Kitt values less
than 2.6% mmol liter1 min. This indicates that insulin
resistance observed in APKD patients might not be as severe as
observed in NIDDM patients. A compensatory hyperinsulinemia
observed in APKD patients may indicate that the function of
pancreatic beta-cells is normal and might be the reason why
patients with APKD are not diabetic.
It has been suggested that insulin resistance is associated with
essential hypertension. However, insulin resistance could not be
simply associated with hypertension in APKD since the same
degree of insulin resistance observed in hypertensive APKD is
present in the normotensive APKD patients. There is evidence
that beta blockers can impair insulin sensitivity and angiotensin
converting enzyme inhibitor can improve insulin sensitivity [20].
Four of seven hypertensive APKD patients were on a beta blocker
but their Kitt values were similar to the ones who were not on a
beta blocker. Moreover, the patient with the highest value of Kitt
(insulin sensitive) was on a beta blocker. Therefore, insulin
resistance observed in hypertensive APKD patients could not be
explained by the effects of medication.
Insulin resistance as assessed by the short insulin tolerance test
or the euglycemic-hyperinsulinemic clamp technique is mostly due
to a reduction in insulin-mediated glucose uptake in the skeletal
muscle [21]. The underlying mechanism whereby insulin resis-
tance occurs has yet to be defined. Transport of glucose into the
cell is mediated by specific glucose-transporter proteins and the
glucose transporter isoform 4 (GLUT-4) is specific to skeletal
muscle. Insulin stimulates the translocation of GLUT-4 from an
intracellular storage pool to the plasma membrane. It has been
suggested that such translocation is defective in insulin resistance
[22]. There is evidence that the membrane cytoskeleton regulates
the traffic of several transporter proteins [231. For example,
Tsakiridis, Vranic and Klip have demonstrated that the cytoskel-
etal actin plays an important role in the correct intracellular
localization of GLUT-4 [24]. Mislocalization of GLUT-4 second-
ary to disassembly of the actin network resulted in a blunt
response of glucose transport in L6 myotubes following insulin
stimulation.
Insulin resistance found in APKD might be due either directly
to the abnormal behavior of polycystic kidney disease gene
proteins and their associated membrane proteins or, more gener-
ally, to the abnormalities of membrane cytoskeleton that occurs in
this disease [10]. We have previously shown that the whole body
insulin sensitivity, as measured by Kitt, is inversely correlated with
the membrane fluidity (reciprocal of the fluorescence anisotropy)
at the core region of mononuclear leukocytes in NIDDM patients
and normal subjects [12]. We postulated that the higher mem-
brane fluidity at this region of the diabetic leukocyte membranes
may hinder conformational changes and aggregation of insulin
receptors, resulting in impaired action of insulin. The enhance-
ment of fluidity at the core region of the membrane was also
found in the mononuclear leukocytes from APKD patients who
were insulin resistant in this present study. As expected, the
degree of membrane lipid fluidity was inversely correlated with
the degree of insulin sensitivity of the whole body in APKD
patients and the normal control group. The relationship between
DPH anisotropy and Kitt was significant in the normal controls
alone and the APKD patients fitted this relationship, that is, the
low Kitt values in the APKD patients were as predicted from their
low DPH anisotropies. However, since almost all the APKD
patients had low Kitt values the range was very poor to test for
correlation, but even so the P value was 0.06.
Compensatory hyperinsulinemia that is the consequence of
insulin resistance was found in the APKD patient group, and the
fasting plasma insulin levels were inversely correlated with the
degree of insulin sensitivity. Bergman, Finegood and Ader have
shown that in the absence of a defect of insulin secretory capacity
of the pancreatic beta-cells, the circulating level of endogenous
insulin correlates well with the degree of insulin sensitivity [25].
This indicates that the function of pancreatic beta-cells is intact in
APKD patients, and explains the normoglycemia observed in the
APKD patients who were insulin resistant. Insulin resistance and
hyperinsulinemia are commonly associated with hypertriglyceri-
demia as parts of the insulin resistance syndrome or metabolic
syndrome [19]. This metabolic syndrome is clearly associated with
increased cardiovascular risks. However, insulin resistance and
hyperinsulinemia found in women with polycystic ovary syndrome
are not associated well with hypertriglyceridemia, and it has been
claimed that the cardiovascular risks are not high in these women
[19]. However, recently several lines of evidence suggest that a
subset of these women may be at increased risk of cardiovascular
disease [26, 27]. A recent cross sectional study of insulin sensitivity
and lipids in a cohort of polycystic ovary subjects clearly showed
that insulin resistance was strongly associated with a low HDL-
cholesterol level 1281. Additionally, Holte et al [291 have shown
that women with polycystic ovary syndrome have an elevated
ambulatory daytime blood pressure, and this might indicate a
pre-hypertensive state. This result may be a further factor for
cardiovascular risks in these women. The observation of increased
cardiovascular risks in a subgroup of women with polycystic ovary
syndrome suggests that there needs to be other factors, which are
likely to be genetic, to account for the tendency to develop
cardiovascular complications in individuals who are insulin resis-
tant.
There is evidence suggesting that APKD increases the risk of
premature cardiovascular disease and sudden death [301. Further-
more, Saggar-Malik and colleagues have shown increased left
ventricular hypertrophy in patients with APKD [31]. All APKD
subjects in their study were normotensive with normal renal
function and had no cardiac valvular defects. Recently, Despres et
al clearly showed that hyperinsulinemia is an important indepen-
dent risk factor for cardiovascular disease [32]. The activity of
erythrocyte Na/Li countertransport (Na/Li CT) has been reported
to be a marker of cardiovascular risk [33]. Clearly, APKD patients
have abnormalities of the kinetics of erythrocyte Na/Li CT. There
is a major genetic influence on erythrocyte Na/Li CT and this
might be linked with a recessive susceptibility gene for essential
hypertension and cardiovascular disease [33, 34]. The activity of
erythrocyte Na/Li CT is influenced by both genetic and environ-
mental factors. Therefore, it might be the superimposition of
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hyperinsulinemia on the susceptibility to cardiovascular compli-
cations detected by abnormal Na/Li CT activity that accounts for
the cardiovascular risk in APKD. It may be that determinations of
insulin resistance and plasma insulin levels will be useful in
identifying patients with APKD who are at particular risk for
cardiovascular disease.
Although patients with APKD showed considerable variation in
their insulin resistance and fasting plasma insulin levels, they did
show significantly higher values for the group as a whole. The
differences were not related to blood pressure. It has been
reported that renal impairment does not cause insulin resistance
until the GFR is less than 40 ml/min [35]. Insulin resistance is then
due to circulating toxins and this is improved by hemodialysis. It
is not an intrinsic result of renal damage. None of the APKD
patients in our study had a plasma creatinine greater than the
normal range and there was no possibility that insulin resistance
could have been caused by renal failure. We were not able to
determine the genotype of our patients, so we cannot comment on
whether this might explain the observed variation in insulin
sensitivity within the APKD group. Certainly, three of the patients
were aged over 60 years and their renal function remained
normal, suggesting that their polycystic kidney disease may be
caused by the PKD 2 gene.
In conclusion, we present evidence of insulin resistance with
compensatory hyperinsulinemia in APKD patients. Abnormal
membrane organization and function found in this disease might
be responsible for the insulin insensitivity. To determine whether
insulin resistance and hyperinsulinemia increase the cardiovascu-
lar risk in APKD needs a larger prospective study. Nevertheless,
whatever the relationships between insulin resistance and APKD
may be, studying the cellular mechanism of insulin resistance in
more detail in APKD, in which a mutant causative protein is
known, may provide an important clue to better understanding
the mechanism of insulin resistance in other situations.
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